Summary

Eligibility
for people ages 12-75 (full criteria)
Location
at UCSF
Dates
study started
study ends around

Description

Summary

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.

Official Title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Keywords

Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP), Erythropoietic Protoporphyria, X-Linked Genetic Diseases, Dersimelagon

Eligibility

Locations

  • University of California at San Francisco
    San Francisco California 94143 United States
  • Marvel Clinical Research, LLC
    Huntington Beach California 92647 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Mitsubishi Tanabe Pharma America Inc.
ID
NCT06144840
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 165 people participating
Last Updated